Cromos Pharma Highlights Psoriasis Awareness and Action Month
August is Psoriasis Awareness and Action Month, which is aimed to educate people about psoriasis and to enlighten patients about its triggers and treatment methods. Cromos Pharma is using this opportunity to underline its commitment to supporting clinical trials to develop new and innovative treatments to improve the lives of millions of psoriasis sufferers around the world.
Psoriasis affects approximately 125 million people globally, which is about 2.2% of the world population. The incidence of psoriasis is most common between the ages of 15 and 25. Studies show that between 10% and 30% of people with psoriasis also develop psoriatic arthritis (inflammation of the joints). Psoriasis is the most common autoimmune disease in the United States, with an estimated 7.5 million Americans who suffer from the condition.
Psoriasis is a complex immune system disorder in which white blood cells, known as T cells, mistakenly attack skin cells, which causes the skin-cell production process to go into overdrive. This results in a build-up of skin cells causing red, scaly patches. The disease is associated with inflammation, triggering several co-morbidities, including inflammatory bowel disease, arthritis, depression, cardiovascular disease and metabolic disease.
The exact cause of psoriasis is unknown. There is a clear genetic predisposition with 40% of patients reporting a family member affected by this disease and it being more prevalent in monozygotic twins. Several gene loci indicate predisposition to developing psoriasis. Common triggers include:
· an injury to the skin (30-40% of patients)
· certain medicines (e.g. lithium)
· weather (cold, dry conditions)
· smoking and heavy alcohol consumption
· throat infections
· immune disorders, such as HIV
· stress (more than 30% of patients)
· hormonal changes
If you would like to learn more about psoriasis, here are some helpful links:
The Psoriasis and Psoriatic Arthritis Alliance (PAPAA)
The Internal Federation of Psoriasis Associates
Cromos Pharma has a strong track record in managing clinical trials designed to find effective treatments for psoriasis and wide-ranging expertise in dermatological clinical research. In addition, the company has vast experience in supporting clinical programs for the development of biologics and biosimilars.
About Cromos Pharma
Cromos Pharma is a US-based, international contract research organization delivering fully integrated clinical research solutions, in all trial phases, across a wide range of therapeutic indications. Our expert team, comprised of 95% MDs, has extensive expertise in study design, medical writing, regulatory affairs, site management, patient recruitment and data management.
Cromos Pharma has experience in delivering success in a wide range of trial types, from biosimilars and generics, to successfully managing trials of novel therapeutics in a wide range of clinical indications. Our team provides full-service solutions to international pharma and biotech companies in high-recruiting regions, assuring exceptional data quality. Cromos Pharma combines global expertise with in-depth experience and knowledge in the US, Central and Eastern Europe, Central Asia, Republic of Georgia, and Türkiye to offer exceptional patient recruitment. Our team has met or reduced enrollment timelines in 95% of conducted trials.
We provide accelerated study start-up timelines in our regions of operation. Regulatory inspections by FDA and EMA and site audits attest to the highest quality of our clinical data.
Established in 2004, Cromos Pharma has strong regional experience that is supported by a global network of offices. Its international HQ is located in Portland, Oregon, USA and its European HQ is in Dublin, Ireland.
If you have any questions or want to find out more about how Cromos Pharma can support your next clinical program please get in touch with us by emailing inquiry@cromospharma.com.
